Erica Andersen-Nissen
Overview
Explore the profile of Erica Andersen-Nissen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
6573
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garrett N, Tapley A, Hudson A, Dadabhai S, Zhang B, Mgodi N, et al.
EClinicalMedicine
. 2025 Feb;
80:103054.
PMID: 39902315
Background: With limited access to mRNA COVID-19 vaccines in lower income countries, and people living with HIV (PLWH) largely excluded from clinical trials, Part A of the multicentre CoVPN 3008...
2.
Mthembu M, Claassen H, Khuzwayo S, Voillet V, Naidoo A, Spillner J, et al.
iScience
. 2024 Nov;
27(11):111137.
PMID: 39563891
HIV causes susceptibility to respiratory pathogens, including tuberculosis (TB), but the underlying immunological mechanisms remain incompletely understood. We obtained whole blood and bronchoalveolar lavage (BAL) from TB-exposed people in the...
3.
Huang Y, Alam S, Andersen-Nissen E, Carpp L, Dintwe O, Flach B, et al.
Viruses
. 2024 Sep;
16(9).
PMID: 39339842
Identifying correlations between immune responses elicited via HIV and non-HIV vaccines could aid the search for correlates of HIV protection and increase statistical power in HIV vaccine-efficacy trial designs. An...
4.
Church E, Bishop E, Fiore-Gartland A, Yu K, Chang M, Jones R, et al.
Immunohorizons
. 2024 Sep;
8(9):695-711.
PMID: 39283647
Cutaneous mycobacterial infections cause substantial morbidity and are challenging to diagnose and treat. An improved understanding of the dermal immune response to mycobacteria may inspire new therapeutic approaches. We conducted...
5.
Kenny A, van Duijn J, Dintwe O, Heptinstall J, Burnham R, Sawant S, et al.
EBioMedicine
. 2024 Sep;
108:105320.
PMID: 39236556
Background: The HVTN 705 Imbokodo trial of 2636 people without HIV and assigned female sex at birth, conducted in southern Africa, evaluated a heterologous HIV-1 vaccine regimen: mosaic adenovirus 26-based...
6.
Garrett N, Dintwe O, Monaco C, Jones M, Seaton K, Church E, et al.
J Acquir Immune Defic Syndr
. 2024 Jun;
96(4):350-360.
PMID: 38916429
Background: An effective vaccine is required to end the HIV pandemic. We evaluated the safety and immunogenicity of a DNA (DNA-HIV-PT123) vaccine with low- or high-dose bivalent (TV1.C and 1086.C...
7.
Dintwe O, Ballweber Fleming L, Voillet V, McNevin J, Seese A, Naidoo A, et al.
Nat Commun
. 2024 Jun;
15(1):5191.
PMID: 38890283
A recent clinical trial demonstrated that Bacille Calmette-Guérin (BCG) revaccination of adolescents reduced the risk of sustained infection with Mycobacterium tuberculosis (M.tb). In a companion phase 1b trial, HVTN 602/Aeras...
8.
Moodie Z, Andersen-Nissen E, Grunenberg N, Dintwe O, Laher Omar F, Kee J, et al.
PLoS Med
. 2024 Mar;
21(3):e1004360.
PMID: 38502656
Background: Adjuvants are widely used to enhance and/or direct vaccine-induced immune responses yet rarely evaluated head-to-head. Our trial directly compared immune responses elicited by MF59 versus alum adjuvants in the...
9.
Chirenje Z, Laher F, Dintwe O, Muyoyeta M, deCamp A, He Z, et al.
J Infect Dis
. 2023 Oct;
230(2):e405-e415.
PMID: 37795976
Background: HVTN 120 is a phase 1/2a randomized double-blind placebo-controlled human immunodeficiency virus (HIV) vaccine trial that evaluated the safety and immunogenicity of ALVAC-HIV (vCP2438) and MF59- or AS01B-adjuvanted bivalent...
10.
Mthembu M, Claassen H, Khuzwayo S, Voillet V, Naidoo A, Nyamande K, et al.
bioRxiv
. 2023 May;
PMID: 37205594
Mechanisms by which HIV causes susceptibility to respiratory pathogens remain incompletely understood. We obtained whole blood and bronchoalveolar lavage (BAL) from people with latent TB infection in the presence or...